We're all set for a new experience. To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open1,987.2
High2,027
Low1,948
Prev. Close2,007.7
Avg. Traded Price1,997.03
Volume10,64,470

MARKET DEPTH

info2
Total bid5.00
Total ask0.00
OrdersQtyBid
152007.7
000
000
000
000
AskQtyOrders
000
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

1,948.0014 hours ago
2,027.009 hours ago
arrow

LOWER/UPPER CIRCUITS

1,576.80
2,365.00
arrow
Gland Pharma Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteInterest Coverage Ratio,is 35.3, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
noteDebt to Equity Ratio,of 0.03 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
notePromoter Pledges,are zero.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : %
Net profit growth 5Y CAGR : %
Gland Pharma Limited is focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. It has established a portfolio of injectable products across various therapeutic areas and delivery systems. It is present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings. Its delivery systems include liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. It is expanding its development and manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products as well as new delivery systems such as pens and cartridges.
personal

Grow your wealth with more research recommendations

+91